BioNexus Gene Lab Corp (BGLC) Income Statement
BGLC 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBGLC revenue and net income
Where BGLC's revenue goes
2025Each bar shows an amount and its share of revenue. BGLC kept −40.2% of revenue as net income.
BGLC profit margins
BGLC growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −21.9% | −12.1% | −8.2% | — |
| Gross profit | −15.8% | −4.8% | −8.8% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BGLC quarterly EPS vs estimates
BioNexus Gene Lab beat the analyst EPS estimate in 0 of the last 1 quarters. Next report: November 13, 2026.
BGLC income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.4M | $9.5M | $9.8M | $10.9M | $13.4M | $11.4M | $126,955 | $212,328 | $107,680 | $0 |
| Cost of revenue | $6.3M | $8.2M | $8.4M | $9.7M | $11.2M | $9.7M | $71,067 | $183,563 | $28,871 | — |
| Gross profit | $1.1M | $1.3M | $1.3M | $1.3M | $2.2M | $1.7M | $55,888 | $28,765 | $78,809 | — |
| Research & development | $50,670 | $47,511 | $54,982 | — | — | — | — | — | — | — |
| Sales, general & admin | $4.1M | $2.0M | $3.0M | $1.7M | $1.2M | $1.3M | $356,641 | $241,930 | — | — |
| Total operating expenses | $4.2M | $2.9M | $3.9M | $1.6M | $1.1M | $446,000 | $331,593 | −$31,136 | $206,715 | $835 |
| Operating income | −$3.2M | −$1.6M | −$2.6M | −$291,177 | $1.1M | $1.3M | −$275,705 | $59,901 | −$127,910 | −$840 |
| Interest income | $83,888 | $147,641 | $68,675 | — | — | — | — | — | — | — |
| Interest expense | $19,542 | $21,146 | $13,929 | $12,479 | $12,973 | $11,313 | $0 | $0 | $0 | $0 |
| Income before taxes | −$3.0M | −$1.6M | −$2.6M | −$303,656 | $1.0M | $1.3M | −$275,705 | $59,901 | −$119,414 | −$835 |
| Income taxes | — | $3,494 | $21,526 | $52,310 | $291,283 | $168,411 | −$29,236 | $33,447 | $4,336 | −$835 |
| Net income | −$3.0M | −$1.6M | −$2.6M | −$355,966 | $751,571 | $1.1M | −$246,469 | $26,454 | −$123,750 | −$835 |
| EBITDA | −$2.8M | −$1.4M | −$2.5M | −$185,758 | $1.2M | $1.4M | −$222,373 | $100,512 | −$104,383 | — |
| EPS (diluted) | −$1.29 | −$0.89 | −$1.61 | −$0.25 | $0.27 | $0.02 | $0.01 | $0.00 | $0.00 | — |
| Gross margin | 14.6% | 13.6% | 13.6% | 11.5% | 16.4% | 15.1% | 44.0% | 13.5% | 73.2% | — |
| Operating margin | −42.5% | −16.5% | −26.5% | −2.7% | 7.9% | 11.2% | −217.2% | 28.2% | −118.8% | — |
| Net margin | −40.2% | −16.8% | −26.9% | −3.3% | 5.6% | 9.6% | −194.1% | 12.5% | −114.9% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76,156 | $22,842 | $483,760 | $2.5M | $2.3M | $2.1M | $2.5M | $2.6M | $2.0M | $2.4M | $2.3M | $2.6M |
| Cost of revenue | $63,174 | $45,573 | $487,743 | $2.2M | $1.9M | $1.8M | $2.2M | $2.3M | $1.7M | $2.0M | $2.0M | $2.2M |
| Gross profit | $12,982 | −$22,731 | −$3,983 | $377,685 | $368,022 | $343,493 | $309,234 | $326,536 | $288,720 | $365,031 | $266,555 | $354,332 |
| Research & development | $13,671 | $14,487 | $11,098 | $14,876 | $12,557 | $12,139 | — | $10,442 | $8,198 | $11,475 | — | — |
| Sales, general & admin | $298,526 | $975,865 | $1.0M | $997,260 | $516,790 | $932,571 | $469,404 | $2.1M | $759,657 | $315,794 | $15,909 | $3.1M |
| Total operating expenses | $295,378 | $548,702 | $1.5M | $1.1M | $979,315 | $961,911 | $3.3M | $1.7M | $29,552 | $444,059 | $2.0M | $2.9M |
| Operating income | −$282,396 | −$571,433 | −$1.0M | −$702,509 | −$611,293 | −$618,418 | −$799,281 | −$1.3M | $259,168 | −$79,028 | $256,708 | −$2.5M |
| Interest income | $21,183 | $17,179 | $9,774 | $20,778 | $29,768 | $23,568 | — | $35,022 | $49,739 | $28,983 | — | — |
| Interest expense | $4,055 | $3,085 | $3,272 | $6,482 | $4,879 | $4,909 | $5,812 | $6,193 | $4,480 | $4,661 | $4,183 | $4,259 |
| Income before taxes | −$286,451 | −$543,575 | −$1.0M | −$708,991 | −$616,172 | −$623,327 | −$422,032 | −$1.3M | $254,688 | −$83,689 | $252,525 | −$2.5M |
| Income taxes | — | — | — | — | — | −$73,713 | — | $1,555 | $55,584 | $20,068 | — | $76,418 |
| Net income | −$286,451 | −$543,575 | −$1.0M | −$708,991 | −$616,172 | −$623,327 | −$348,319 | −$1.3M | $199,104 | −$103,757 | $307,417 | −$2.6M |
| EBITDA | −$240,059 | −$496,608 | −$989,647 | −$665,636 | −$569,560 | −$546,916 | — | −$1.3M | $290,625 | −$49,442 | — | −$2.5M |
| EPS (diluted) | −$0.12 | −$0.22 | −$0.52 | −$0.40 | −$0.34 | −$0.03 | −$0.19 | −$0.75 | $0.11 | −$0.06 | $0.17 | −$1.56 |
| Gross margin | 17.0% | −99.5% | −0.8% | 14.8% | 16.3% | 16.1% | 12.3% | 12.4% | 14.6% | 15.3% | 11.7% | 13.9% |
| Operating margin | −370.8% | −2,501.7% | −213.3% | −27.6% | −27.0% | −28.9% | −31.7% | −50.9% | 13.1% | −3.3% | 11.3% | −99.0% |
| Net margin | −376.1% | −2,379.7% | −214.2% | −27.9% | −27.3% | −29.2% | −13.8% | −51.1% | 10.1% | −4.4% | 13.5% | −102.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BGLC's financial statements (latest annual report filed April 14, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BGLC financial results
In fiscal year 2025 (ended December 31, 2025), BioNexus Gene Lab reported revenue of $7.4 million, down 21.9% from the year before. It had a net loss of $3.0 million, a net profit margin of −40.2%. Diluted earnings per share came to −$1.29. Over five years revenue grew at an average rate of −8.2% a year.
See the BGLC stock overview for the latest quote and news, or the BGLC chart for price history and technical indicators.
BGLC income statement FAQ
What is BioNexus Gene Lab's annual revenue?
BioNexus Gene Lab reported total revenue of $7.4 million for fiscal year 2025, which ended on December 31, 2025. That was down 21.9% from $9.5 million the previous year.
Is BioNexus Gene Lab profitable?
No. BioNexus Gene Lab reported a net loss of $3.0 million in fiscal 2025, a net profit margin of −40.2%; its operating margin was −42.5%.
What is BioNexus Gene Lab's gross margin?
BioNexus Gene Lab's gross margin was 14.6% in fiscal 2025: for every $100 of revenue, BioNexus Gene Lab kept $15 after the direct cost of its products and services.
How much does BioNexus Gene Lab spend on research and development?
BioNexus Gene Lab spent $0.1 million on research and development in fiscal 2025, 0.7% of revenue.
How fast is BioNexus Gene Lab growing?
Revenue grew −8.2% a year on average over the last five fiscal years, from $11.4 million to $7.4 million.
What are BioNexus Gene Lab's earnings per share?
BioNexus Gene Lab earned $-1.29 per diluted share in fiscal 2025, compared with $-0.89 a year earlier.
When will BioNexus Gene Lab report its next earnings?
BioNexus Gene Lab is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does BioNexus Gene Lab's fiscal year end?
BioNexus Gene Lab's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 14, 2026.